Literature DB >> 22875099

Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis.

P Wipfler1, A Heikkinen, A Harrer, G Pilz, A Kunz, S M Golaszewski, R Reuss, Patrick Oschmann, J Kraus.   

Abstract

Inflammatory serum parameters are intensely investigated in the search of biomarkers for disease activity and treatment response in multiple sclerosis (MS). A reason for contradictory results might be the timing of blood collection for analyzing serum concentrations of inflammatory parameters which are subject to diurnal changes. We included 34 untreated patients with relapsing-remitting MS and 34 age- and sex-matched healthy controls. 12 MS patients showed acute disease activity in corresponding MRI scans. Blood samples were obtained at 7.00, 11.00 am, 2.30, 6.00 and 9.30 pm within 1 day. We determined serum levels of cortisol and inflammatory markers including soluble tumor necrosis factor-beta (sTNF-β), soluble TNF-Receptor-1 (sTNF-R1) and -2 (sTNF-2), soluble vascular adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion molecule-1 (sICAM-1) by ELISA. We observed significantly higher serum levels of sTNF-R1 (p < 0.001) and sTNF-R2 (p < 0.001) in the morning and a significant decline of sICAM-1 (p < 0.005) and sVCAM-1 (p < 0.001) in the afternoon in both, MS patients and healthy controls. Comparison of diurnal serum levels between MS patients with active versus with non-active disease revealed significantly higher serum levels of sVCAM-1 (p < 0.05) around noon and in the early afternoon in MS patients with active disease. A significant decline of sICAM-1 (p < 0.05) in the afternoon was seen in MS patients with active and non-active disease. Our data indicate that increased awareness of potential diurnal serum concentration changes of biomarkers can eliminate one major cause of biased data as they occur in most of the investigated immunological parameters.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22875099     DOI: 10.1007/s00415-012-6622-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  25 in total

Review 1.  The tick-tock of the biological clock.

Authors:  M W Young
Journal:  Sci Am       Date:  2000-03       Impact factor: 2.142

Review 2.  The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications.

Authors:  J J Archelos; H P Hartung
Journal:  Mol Med Today       Date:  1997-07

3.  Chronotherapy using corticosteroids for multiple sclerosis relapses.

Authors:  Lea Glass-Marmor; Tamar Paperna; Yaara Ben-Yosef; Ariel Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10-20       Impact factor: 10.154

4.  Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis.

Authors:  G V McDonnell; S A McMillan; J P Douglas; A G Droogan; S A Hawkins
Journal:  J Neuroimmunol       Date:  1998-05-15       Impact factor: 3.478

5.  Circadian variation in cell-adhesion molecule expression by normal human leukocytes.

Authors:  Gary D Niehaus; Elyce Ervin; Amit Patel; Kamal Khanna; Vincent W Vanek; Diana L Fagan
Journal:  Can J Physiol Pharmacol       Date:  2002-10       Impact factor: 2.273

6.  Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis.

Authors:  A Grasser; A Möller; H Backmund; A Yassouridis; F Holsboer
Journal:  Exp Clin Endocrinol Diabetes       Date:  1996       Impact factor: 2.949

7.  Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis.

Authors:  J Kraus; P Oschmann; B Engelhardt; C Schiel; C Hornig; R Bauer; A Kern; H Traupe; W Dorndorf
Journal:  Acta Neurol Scand       Date:  1998-08       Impact factor: 3.209

8.  Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging.

Authors:  H P Hartung; K Reiners; J J Archelos; M Michels; P Seeldrayers; F Heidenreich; K W Pflughaupt; K V Toyka
Journal:  Ann Neurol       Date:  1995-08       Impact factor: 10.422

9.  Immunomodulation by chronobiologically-based glucocorticoids treatment for multiple sclerosis relapses.

Authors:  Lea Glass-Marmor; Tamar Paperna; Yanna Galboiz; Ariel Miller
Journal:  J Neuroimmunol       Date:  2009-03-28       Impact factor: 3.478

10.  Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis.

Authors:  P Rieckmann; B Altenhofen; A Riegel; B Kallmann; K Felgenhauer
Journal:  Mult Scler       Date:  1998-06       Impact factor: 6.312

View more
  11 in total

1.  Elevated plasma homocysteine levels are associated with disability progression in patients with multiple sclerosis.

Authors:  Sayonara Rangel Oliveira; Tamires Flauzino; Beatriz Sardinha Sabino; Ana Paula Kallaur; Daniela Frizon Alfieri; Damacio Ramon Kaimen-Maciel; Helena Kaminami Morimoto; Elaine Regina Delicato de Almeida; Marcell Alysson Batisti Lozovoy; Edna Maria Vissoci Reiche; Isaias Dichi; Andréa Name Colado Simão
Journal:  Metab Brain Dis       Date:  2018-05-24       Impact factor: 3.584

Review 2.  Potential Circadian Rhythms in Oligodendrocytes? Working Together Through Time.

Authors:  Christopher S Colwell; Cristina A Ghiani
Journal:  Neurochem Res       Date:  2019-03-25       Impact factor: 3.996

3.  MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.

Authors:  Donna Wilcock; Gregory Jicha; Deborah Blacker; Marilyn S Albert; Lina M D'Orazio; Fanny M Elahi; Myriam Fornage; Jason D Hinman; Janice Knoefel; Joel Kramer; Richard J Kryscio; Melissa Lamar; Abhay Moghekar; Jillian Prestopnik; John M Ringman; Gary Rosenberg; Abhay Sagare; Claudia L Satizabal; Julie Schneider; Sudha Seshadri; Sandeepa Sur; Russell P Tracy; Sevil Yasar; Victoria Williams; Herpreet Singh; Lidiya Mazina; Karl G Helmer; Roderick A Corriveau; Kristin Schwab; Pia Kivisäkk; Steven M Greenberg
Journal:  Alzheimers Dement       Date:  2021-01-21       Impact factor: 16.655

Review 4.  Circadian Variation in Efficacy of Medications.

Authors:  James C Walton; William H Walker; Jacob R Bumgarner; O Hecmarie Meléndez-Fernández; Jennifer A Liu; Heather L Hughes; Alexis L Kaper; Randy J Nelson
Journal:  Clin Pharmacol Ther       Date:  2020-11-29       Impact factor: 6.903

5.  Distinct plasma immune signatures in ME/CFS are present early in the course of illness.

Authors:  Mady Hornig; José G Montoya; Nancy G Klimas; Susan Levine; Donna Felsenstein; Lucinda Bateman; Daniel L Peterson; C Gunnar Gottschalk; Andrew F Schultz; Xiaoyu Che; Meredith L Eddy; Anthony L Komaroff; W Ian Lipkin
Journal:  Sci Adv       Date:  2015-02       Impact factor: 14.136

6.  Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197.

Authors:  S De Buck; W Hueber; A Vitaliti; F Straube; C Emotte; G Bruin; R Woessner
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-11-09

Review 7.  Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse.

Authors:  Elizabeth A Mills; Ali Mirza; Yang Mao-Draayer
Journal:  Front Neurol       Date:  2017-03-29       Impact factor: 4.003

Review 8.  Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Int J Mol Sci       Date:  2018-04-16       Impact factor: 5.923

Review 9.  Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research.

Authors:  Sid E O'Bryant; Veer Gupta; Kim Henriksen; Melissa Edwards; Andreas Jeromin; Simone Lista; Chantal Bazenet; Holly Soares; Simon Lovestone; Harald Hampel; Thomas Montine; Kaj Blennow; Tatiana Foroud; Maria Carrillo; Neill Graff-Radford; Christoph Laske; Monique Breteler; Leslie Shaw; John Q Trojanowski; Nicole Schupf; Robert A Rissman; Anne M Fagan; Pankaj Oberoi; Robert Umek; Michael W Weiner; Paula Grammas; Holly Posner; Ralph Martins
Journal:  Alzheimers Dement       Date:  2014-10-01       Impact factor: 21.566

10.  Biomarkers in Multiple Sclerosis: An Up-to-Date Overview.

Authors:  Serafeim Katsavos; Maria Anagnostouli
Journal:  Mult Scler Int       Date:  2013-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.